110424 ⎘
Reverse transcribing RNA viruses; Details; Retroviridae; Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERY
#2TDP-43 Interference Peptides, Methods, and Uses Thereof
#3MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERY
#4Molecules for organelle-specific protein delivery
#5COMPOSITIONS AND METHODS FOR PRODUCING AND OPTIMIZING VIRAL VECTOR PRODUCER CELLS FOR CELL AND GENE THERAPY
#6DELIVERY OF THERAPEUTIC RNAS VIA ARRDC1-MEDIATED MICROVESICLES
#7Expression systems comprising nucleic acids encoding HIV-1 protease cleavage site polypeptides
#8Chloride salt of TAT-NR2B9C
#9USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES
#10Antigen Delivery Vectors and Constructs
#11Molecules for organelle-specific protein delivery
#12HIV/SIV Nef fusion proteins for exosome targeted expression
#13Fusion proteins comprising an anti-CD40 antibody and cancer antigens
#14Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes
#15Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles
#16Compositions and methods for treating diseases by inhibiting exosome release
#17HIV vaccines comprising one or more population episensus antigens
#18HIV vaccines comprising one or more population episensus antigens
#19Nucleic acids encoding anti-CD40 antibodies
#20Antiviral vaccines with improved cellular immunogenicity
#21Chloride salt of TAT-NR2B9C
#22Methods of inducing an immune response against HIV-1 utilizing nucleic acids encoding polypeptides containing HIV-1 protease cleavage sites
#23JNK Inhibitor Molecules For Treatment Of Various Diseases
#24PROFILING PEPTIDES AND METHODS FOR SENSITIVITY PROFILING
#25Antibacterial compositions, methods of making and use thereof
#26Therapy for subarachnoid hemorrhage and ischemia
#27Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
#28COMPOSITIONS AND METHODS FOR STUDYING THE TAT GENE
#29Use of a HIV derived accessory protein for the reactivation of latent HIV
#30Method for preparing cells expressing Nef-fusion proteins associated with exosomes
#31NOVEL TRANSPORTER CONSTRUCTS AND TRANSPORTER CARGO CONJUGATE MOLECULES
#32Antiviral vaccines with improved cellular immunogenicity
#33CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
#34Nanoparticles carrying immunogenic peptides targeting HIV-1 protease cleavage sites
#35SOLID PHASE PEPTIDE SYNTHESIS
#36Profiling peptides and methods for sensitivity profiling
#37Chloride salt of TAT-NR2B9c
#38Compositions and methods for treating diseases by inhibiting exosome release
#39Antibacterial compositions, methods of making and use thereof
#40HIV peptide vaults and methods of making and using thereof
#41Anti-CD40 antibodies
#42Generation of human anti-HIV-1 ENV monoclonal antibodies with neutralizing activity from humanized mice infected with HIV-1
#43Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising gag, pol, vif and nef epitopes
#44Conditionally immortalized long-term stem cells and methods of making and using such cells
#45PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES
#46METHODS FOR SYNTHESIZING PEPTIDE-TAGGED PEGYLATED CHITOSAN
#47Method of inducing an immune response by administering exosomes comprising Nef-fusion proteins
#48Compositions and methods for treating diseases by inhibiting exosome release
#49Profiling peptides and methods for sensitivity profiling
#50Consensus/ancestral immunogens
#51Uncoupling growth and protein production
#52Methods of inducing an immune response against HIV by administering immunogenic peptides obtained from protease cleavage sites
#53Profiling peptides and methods for sensitivity profiling
#54Multitarget-directed bio-inorganic hybrid structure
#55Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides
#56Compositions and methods for exosome targeted expression
#57Cell-permeable peptide system for treating diseases caused by glutamate excitotoxicity
#58Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
#59HIV vaccines comprising one or more population episensus antigens
#60HIV and immunogenic peptide sequences and compositions
#61Antiviral vaccines with improved cellular immunogenicity
#62Solid phase peptide synthesis
#63Pharmaceutical composition for suppressing cell transplant rejection
#64Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
#65Cell-permeable peptide system for treating diseases caused by glutamate excitotoxicity
#66Chloride salt of TAT-NR2B9c
#67Method of making an anti-CD40 antibody
#68Stitched polypeptides
#69Methods and pharmaceutical compositions for the treatment of cancer
#70JNK inhibitor molecules for treatment of various diseases
#71Use of a HIV derived accessory protein for the reactivation of latent HIV
#72Transactivator of transcription (TAT) proteins and preparation method
#73PTD-SMAD7 THERAPEUTICS
#74Modulation of cellular localization of cyclin C
#75Cell penetrating protein adaptor molecules and their application in research and medicine
#76ADAM10 INHIBITION TO TREAT FRAGILE X SYNDROME
#77Interferon Regulatory Factor 1 (IRF1) Decoys and Methods of Use Thereof
#78Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
#79Recombinant protein bodies as immunogen-specific adjuvants
#80Therapy for subarachnoid hemorrhage and ischemia
#81CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
#82Cell permeable inhibitors of the scaffold protein plenty of SH3 domains (POSH) or Sh3Rfl
#83Selective Sensitization of Cancer Cells to, and Selective Protection of Non-Cancer Cells from Genotoxic Therapies
#84CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
#85PTD-SMAD7 therapeutics
#86Antiviral vaccines with improved cellular immunogenicity
#87Assay for Screening of Anti-Viral Compounds That Inhibit Specific Interaction Interfaces Between Cullin5 and an ElonginB/ElonginC/ CBF-beta/HIV-1 Vif Complex
#88Conditionally immortalized long-term stem cells and methods of making and using such cells
#89HIV peptides and immunogenic compositions
#90Peptide inhibitors as novel anti-HIV therapeutics
#91Antigen delivery vectors and constructs
#92HIV consensus envelope sequences and methods for using the same
#93Anti-CD40 antibodies
#94HIV-1 south african subtype C env proteins
#95hTERT sequences and methods for using the same
#96Antigen presenting cell targeted anti-viral vaccines
#97Compositions and methods for treating AIDS or cancer by inhibiting the secretion of microparticles
#98Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides
#99Bioresorbable nonlamellar microparticles and uses thereof
#100Method of purifying HIV/SIV Nef from exosomal fusion proteins
#101Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope
#102Method of improving immune function in HIV-infected subjects on HAART by administering HIV-1 TAT
#103Peptide Sequences of HIV polypeptides and compositions thereof
#104Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
#105Compositions and methods for treating cancer by inhibiting the secretion of microparticles
#106HIV consensus envelope sequences and methods for using the same
#107MODIFIED VACCINIA ANKARA VIRUS VARIANT
#108Antigen delivery vectors and constructs
#109Modified Vaccinia Ankara virus variant and cultivation method
#110VIRAL VECTORS ENCODING A DNA REPAIR MATRIX AND CONTAINING A VIRION-ASSOCIATED SITE SPECIFIC MEGANUCLEASE FOR GENE TARGETING
#111EXPRESSION CASSETTES ENDCODING HIV-1 SOUTH AFRICAN SUBTYPE C MODIFIED PROTEINS
#112EXPRESSION OF HIV POLYPEPTIDES AND PRODUCTION OF VIRUS-LIKE PARTICLES
#113Targeted particles and methods of using the same
#114HIV-1 clade a consensus sequences, antigens, and transgenes
#115Chimeric HIV fusion proteins as vaccines
#116NOVEL TRANSPORTER CONSTRUCTS AND TRANSPORTER CARGO CONJUGATE MOLECULES
#117Fusion proteins of HIV regulatory/accessory proteins
#118Fusion proteins of HIV regulatory/accessory proteins
#119Tat-Based Vaccine Compositions and Methods of Making and Using Same
#120TAT Protein for preventing or treating AIDS
#121Mutant tat proteins and uses thereof
#122Compositions and Methods for Modulating Immunodeficiency Virus Transcription
#123Tat-Based Tolerogen Compositions and Methods for Making and Using Same
#124Agents for treatment of HCV and methods of use
#125Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses
#126Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy
#127Antiviral vaccines with improved cellular immunogenicity
#128Efficient transport into white blood cells
#129Antigen delivery vectors and constructs
#130Immunogenic compositions for inducing an immune response to HIV
#131Process for the production of biologically active HIV-1 tat protein
#132Screening method for the identification of inhibitors of HIV Tat methylation by the lysine methyltransferase Set7/9
#133Enhanced immune response against infections
#134Human immunodeficiency virus and uses thereof
#135Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses
#136Recombinant Protein Bodies as Immunogen-Specific Adjuvants
#137Covalently linked complexes of HIV TAT and ENV PROTEINS
#138Identification, optimization and use of cryptic HLA-B7 epitopes for immunotherapy
#139Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
#140CATIONIC CORE-SHELL PEPTIDE NONOPARTICLES
#141Modified Vaccinia Ankara virus variant and cultivation method
#142POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF
#143Modified Tat Oyi protein with enhanced immunogenicity
#144Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides
#145Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen
#146TAT-BASED IMMUNOMODULATORY COMPOSITIONS AND METHODS FOR THEIR DISCOVERY AND USE
#147Dendritic cell vaccines
#148Modified virus variant
#149Modified Vaccinia Ankara virus variant
#150Tat DNA sequences, gene constructs, vaccine and processes thereof
#151COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION
#152LENTIVIRUS-BASED IMMUNOGENIC VECTORS
#153VIRAL VECTORS FOR DELIVERING VACCINES FOR HIV AND OTHER INFECTIOUS DISEASES
#154MAGE-A3/HPV 16 PEPTIDE VACCINES FOR HEAD AND NECK CANCER
#155Expression of HIV polypeptides and production of virus-like particles
#156Cell permeable peptide
#157Inducible gene expression
#158HIV COMBINATION VACCINE AND PRIME BOOST
#159Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
#160METHODS AND COMPOSITIONS FOR IDENTIFYING COMPOUNDS THAT INHIBIT HIV-1 SUBUNIT-SPECIFIC REVERSE TRANSCRIPTASE
#161Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
#162POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF
#163Combination Immunogene Therapy
#164Conditionally immortalized long-term stem cells and methods of making and using such cells
#165Anti-CD40 targeted fusion proteins
#166Recombinant MVA virus and the use thereof
#167Therapeutic peptides for the treatment of metastatic cancer
#168Fusion protein with HIV antigen
#169Process for making oligopeptides
#170IMMUNOGENICITY USING A COMBINATION OF DNA AND VACCINIA VIRUS VECTOR VACCINES
#171Modified vaccinia ankara virus variant and cultivation method
#172ANIMAL MODEL FOR HIV INDUCED DISEASE
#173Recombinant MVA virus
#174COMPOSITION AND METHOD FOR TREATING VIRAL INFECTION
#175Anti-CD40 antibodies
#176FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#177BIOLOGICAL AGENTS ACTIVE IN CENTRAL NERVOUS SYSTEM
#178Nuclear translocation peptide
#179VACCINE
#180Stitched polypeptides
#181Non-M, non-O HIV-1 strains, fragments and uses
#182Antigen delivery vectors and constructs
#183Broadly Representative Antigen Sequences and Method for Selection
#184Antigen delivery vectors and constructs
#185MAGE-A3/HPV 16 PEPTIDE VACCINES FOR HEAD AND NECK CANCER
#186VPR FUNCTION AND ACTIVITY
#187HPV vaccines and methods for using the same
#188Fluorescent amino acid derivatives
#189Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
#190MEMBRANE-PERMEANT PEPTIDE COMPLEXES FOR TREATMENT OF SEPSIS
#191Modified Vaccinia Ankara virus variant
#192MODIFIED HIV ENV POLYPEPTIDES
#193Method for Identification and Development of Therapeutic Agents
#194Method of inhibiting HIV replication utilizing the P7 nucleocapsid protein
#195NOVEL METHOD AND COMPOSITIONS
#196PEPTIDES SEQUENCES AND COMPOSITIONS
#197Fusion proteins of HIV regulatory/accessory proteins
#198Recombinant vectors based on the modified vaccinia ankara virus (MVA) as preventive and therapeutic vaccines against AIDS
#199Fusion proteins of HIV regulatory/accessory proteins
#200Polycistronic HIV vector constructs
#201CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
#202HIV-1 Tat, or derivatives thereof for prophylactic and therapeutic vaccination
#203Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof
#204Cell-permeable peptide inhibitors of the JNK signal transduction pathway
#205Modified HIV Env polypeptides
#206Fusion protein of HIV regulatory/accessory proteins
#207Antiviral peptide and antiviral agent
#208Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses
#209Methylated tat polypeptides and methods of use thereof
#210Methods and compositions for immunization against hiv
#211Vaccines against aids comprising cmv/r-nucleic acid constructs
#212Epitope-enhancement of a human cd4 hiv epitope
#213CHIMERIC HIV FUSION PROTEINS AS VACCINES
#214HIV-GAG CODON-OPTIMISED DNA VACCINES
#215TAT-BASED TOLEROGEN COMPOSITIONS AND METHODS FOR MAKING AND USING SAME
#216Expression system for enhancing solubility and immunogeneicity of recombinant proteins
#217TAT-BASED VACCINE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
#218Modifications of HIV Env, Gag, and Pol enhance immunogenicity for genetic immunization
#219Genetic constructs and compositions comprising RRE and CTE and uses thereof
#220Simian tropic, recombinant human immunodeficiency-1 viruses
#221Modified Vaccinia Ankara virus variant
#222NOVEL USE
#223INTRACELLULAR DELIVERY OF SMALL MOLECULES, PROTEINS, AND NUCLEIC ACIDS
#224HIV-1 subtype isolate regulatory/accessory genes, and modification and derivatives thereof
#225Methods for activating peripheral blood mononuclear cells (PBMCs) by administering human immunodeficiency virus (HIV) Tat under physiological oxygen levels
#226Immunological compositions
#227FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#228Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
#229TSG101-GAG INTERACTION AND USE THEREOF
#230Cell permeable bioactive peptide conjugates
#231Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein
#232Modified vaccinia ankara virus variant and cultivation method
#233Modified vaccinia ankara virus variant and cultivation method
#234Renta: an HIV immunogen and uses thereof
#235Covalently-linked complexes of HIV Tat and Env proteins
#236High-throughput assay for virus entry and drug screening
#237HIV vif mutants
#238Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
#239Expression system for enhancing solubility and immunogeneicity of recombinant proteins
#240METAL BINDING PROTEINS AND ASSOCIATED METHODS
#241Lentiviral packaging constructs
#242Expression of HIV polypeptides and production of virus-like particles
#243Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens
#244Anti-HIV immunogens and methods for inducing an immune response
#245Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
#246POLYEPITOPIC PROTEIN FRAGMENTS OF THE E6 AND E7 PROTEINS OF HPV, THEIR PRODUCTION AND THEIR USE PARTICULARLY IN VACCINATION
#247Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof
#248Mutated HIV Nef for modulating immunity
#249CELLULAR IMMUNITY TEST WITH PEPTIDES ATTACHED TO A SOLID SUPPORT
#250VACCINE
#251Immunodeficiency recombinant poxvirus
#252Process for producing stable HIV Th-CTL peptides
#253Polyvalent Immunogen
#254Multimerization of HIV-1 Vif protein as a therapeutic target
#255Intracellular delivery of osteoinductive proteins and peptides
#256Tat-based immunomodulatory compositions and methods of their discovery and use
#257Adeno-associated virus AAV Rep78 major regulatory protein mutants thereof and uses thereof
#258Methods of inducing mucosal immunity
#259Epitope escape mutations
#260Agents for treatment of HCV and methods of use
#261COMPOSITION OF MATTER COMPRISING PRIMARY NUCLEIC ACID COMPONENT
#262VACCINE COMPRISING GP120 AND NEF AND/OR TAT FOR THE IMMUNIZATION AGAINST HIV
#263FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#264Generation of potent dominant negative transcriptional inhibitors
#265POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE B POLYPEPTIDES, POLYPEPTIDES, AND USES THEREOF
#266FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#267HIV-1 Clade A consensus sequences, antigens, and transgenes
#268Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2
#269Modified Vaccinia Ankara virus variant
#270FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#271Cytoplasmic Localization Dna and Rna
#272TRANSIENTLY IMMORTALIZED CELLS FOR USE IN GENE THERAPY
#273Tat-Based Tolerogen Compositions and Methods of Making and Using Same
#274HPV 16 peptide vaccine for head and neck cancer
#275Human Immunodeficiency Virus Vaccine
#276Lentiviral packaging constructs
#277Vaccine Composition Comprising a Class II Cmh Lignd Coupled With an Antigen, Method for the Preparation and the Use Thereof
#278Use of Microparticles for Antigen Delivery
#279VACCINE
#280Tat-Based vaccine Compositions and Methods of Making and Using Same
#281Immunomodulating Compositions, Uses Therefore and Processes for Their Production
#282Vaccine for prevention and treatment of HIV-infection
#283Methods and compositions for treating inflammatory disorders
#284COMPOSITION AND METHOD FOR TREATING HIV INFECTION
#285Non-M, non-O HIV-1 strains, fragments and uses
#286Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv
#287Animal model for HIV induced disease
#288Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins
#289Metal binding proteins and associated methods
#290Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
#291Attenuated vif DNA immunization cassettes for genetic vaccines
#292Viral deconstruction through capsid assembly in vitro
#293Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications
#294Recombinant MVA virus, and the use thereof
#295Recombinant MVA virus, and the use thereof
#296Method for production of bioresorable microparticles, microparticles thus obtained and use thereof
#297Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications
#298Vaccine
#299Hiv-gag codon-optimised dna vaccines
#300METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF VIRAL AND BACTERIAL INFECTIONS